Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
1995
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AE01
|
| gptkbp:brand |
saquinavir
|
| gptkbp:chemicalFormula |
C38H50N6O5
|
| gptkbp:contraindication |
severe liver impairment
concurrent use with certain antiarrhythmics concurrent use with ergot derivatives |
| gptkbp:drugClass |
protease inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invirase
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Saquinavir
gptkb:F._Hoffmann-La_Roche_AG |
| gptkbp:bfsLayer |
7
|